Trial reportInternational journal of medical sciences2013
Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis.
Trial report in International journal of medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Antibiotic stewardship interventions in hospitals in low-and middle-income countries: a systematic review.Bulletin of the World Health Organization · 2018Pooled it
- Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.The Cochrane database of systematic reviews · 2017Pooled it
- Interventions to improve antibiotic prescribing practices for hospital inpatients.The Cochrane database of systematic reviews · 2017Pooled it
- Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026Review
- A biomarker-guided framework for corticosteroid treatment stratification in acute exacerbation of idiopathic pulmonary fibrosis.Frontiers in pharmacology · 2026Article
- Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments.Journal of thoracic disease · 2024Review
- Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- Acute exacerbation of interstitial lung disease associated with rheumatic disease.Nature reviews. Rheumatology · 2022Review
- Acute exacerbation of interstitial lung disease in the intensive care unit.World journal of critical care medicine · 2022Review
- The Role of Serum 1,25-Dihydroxy Vitamin D3 and PCT in Idiopathic Pulmonary Fibrosis.International journal of general medicine · 2022Article
- Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases.Respiratory medicine · 2021Review
- Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms.American journal of respiratory and critical care medicine · 2020Article
- A behavioural approach to specifying interventions: what insights can be gained for the reporting and implementation of interventions to reduce antibiotic use in hospitals?The Journal of antimicrobial chemotherapy · 2020Article
- Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy.Breathe (Sheffield, England) · 2019Review
- Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.Current pulmonology reports · 2019Article
- Recommendations for perioperative management of lung cancer patients with comorbidities.General thoracic and cardiovascular surgery · 2018Review
- The Management of Patients With Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2018Review
- Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Procalcitonin-guided diagnosis and antibiotic stewardship revisited.BMC medicine · 2017Review
- Acute Exacerbation in Interstitial Lung Disease.Frontiers in medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectTo assess the clinical value of procalcitonin to guide antibiotic therapy in acute exacerbations of idiopathic pulmonary fibrosis.
methodsPatients with acute exacerbations of idiopathic pulmonary fibrosis were randomly assigned to the procalcitonin-guided group (antibiotic use guided by a procalcitonin threshold of 0.25 ng/ml) or the routine treatment group (antibiotic use according to routine practice). Follow up of clinical outcomes were assessed at baseline and 30 days later.
resultsBaseline characteristics including demographics, clinical characteristics and laboratory results were similar between groups. PCT guidance resulted in a significant reduction of antibiotic treatment duration (8.7 ± 6.6 compared to 14.2 ± 5.2 days in the routine treatment group). Fewer patients were exposed to antibiotics treatment in the PCT group (26 patients) compared with the control group (35 patients). Treatment success, mortality rate, days of hospitalization and ventilation therapy were similar between the two groups.
conclusionProcalcitonin-guided antibiotic therapy of patients with acute exacerbation of idiopathic pulmonary fibrosis may result in reduced exposure to antibiotics without adversely affecting patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.